Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

ClinicalTrials.gov ID: NCT03894215

Public ClinicalTrials.gov record NCT03894215. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy and safety of AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or with AGEN1884 (Treatment Arm 2- combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy. The study is not intended to compare the efficacy of the 2 experimental arms. Rather, the efficacy of each arm will be evaluated against its relevant historical controls as appropriate.

Study identification

NCT ID
NCT03894215
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Agenus Inc.
Industry
Enrollment
211 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2019
Primary completion
Mar 25, 2025
Completion
Mar 25, 2025
Last update posted
Mar 26, 2026

2019 – 2025

United States locations

U.S. sites
42
U.S. states
18
U.S. cities
39
Facility City State ZIP Site status
University of Alabama at Birmingham School of Medicine Birmingham Alabama 35233-1802
University of South Alabama Mitchell Cancer Institute Mobile Alabama 36604
Arizona Oncology - Biltmore Cancer Center Phoenix Arizona 85016
Arizona Oncology - Tucson - Wilmot Road Location Tucson Arizona 85711
University of California, San Diego (UCSD) - Moores Cancer Center La Jolla California 92093
UCLA- Women's Health Clinical Research Unit (WHCRU) Los Angeles California 90095
Gynecologic Oncology Associates Newport California 92663
California Pacific Medical Center San Francisco California 94115-1821
University of California, San Francisco Medical Center San Francisco California 94158
Baptist MD Anderson Cancer Center Jacksonville Florida 32207
Moffitt Cancer Center Tampa Florida 33612
Northside Hospital Atlanta Georgia 30342
St Joseph's Hospital Savannah Georgia 31405-6015
Community Health Network - North Cancer Center Indianapolis Indiana 46250
University of Kentucky Albert B. Chandler Hospital Lexington Kentucky 40536
Ochsner Clinic Foundation New Orleans Louisiana 70121
MD Anderson Cancer Center at Cooper Camden New Jersey 08103
University of New Mexico Cancer Center Albuquerque New Mexico 87102
Northwell Health Monter Cancer Center Lake Success New York 11042
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York New York 10016
SUNY Upstate Medical University Syracuse New York 13210
Albert Einstein College of Medicine The Bronx New York 10461
Levine Cancer Institute Charlotte North Carolina 28204
FirstHealth Outpatient Cancer Center Pinehurst North Carolina 28374
MetroHealth Medical Center Cleveland Ohio 44109
The Ohio State University Wexner Medical Center Columbus Ohio 43210
Columbus NCORP Columbus Ohio 43215
Stephenson Cancer Center Oklahoma City Oklahoma 73104-5418
Oklahoma Cancer Specialists and Research Institute, LLC Tulsa Oklahoma 74146
Willamette Valley Cancer Institute Eugene Oregon 97401
Northwest Cancer Specialists, P.C. Portland Oregon 97227
Penn Medicine - Jordan Center for Gynecologic Cancer Philadelphia Pennsylvania 19104-5127
WellSpan Gynecologic Oncology York Pennsylvania 17403
Women & Infants Hospital of Rhode Island Providence Rhode Island 02905
Texas Oncology Surgical Specialists - Austin Central Austin Texas 78745
Texas Oncology - Bedford Bedford Texas 76022
Texas Oncology - Dallas - Presbyterian Cancer Center Dallas Texas 75231
The University of Texas Southwestern Medical Center Dallas Texas 75390
Texas Oncology - Fort Worth Cancer Center Fort Worth Texas 76104
Texas Oncology - San Antonio Medical Center San Antonio Texas 78240
Texas Oncology - The Woodlands The Woodlands Texas 77380
Texas Oncology Tyler Texas 75702

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03894215, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 26, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03894215 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →